Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06952699 · ClinicalTrials.gov registry record · Phase 2

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

A Phase 2 study of Narcolepsy Type 2, sponsored by Takeda.

Recruiting
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT06952699: Recruiting Phase 2 study of Narcolepsy Type 2, sponsored by Takeda.

NCT06952699 is a Phase 2 study of Narcolepsy Type 2 that is actively recruiting participants, run by Takeda. The registered enrollment target is 88 participants, below the 112-participant average among 4 other Narcolepsy Type 2 trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06952699, a Phase 2 study of Narcolepsy Type 2, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families challenging, impacting their quality of life. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with NT2 tolerate it. Researchers also want to find out if TAK-360 can help people with NT2 stay awake and determine the right dosage needed to do that. Participants will be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo in the treatment period. The placebo is a pill that looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Primary Outcome

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG TAK-360

Study Locations (20)

California

  • Takeda Site 14 - Redwood City
  • Takeda Site 10 - Santa Ana

Florida

  • Takeda Site 13 - Brandon
  • Takeda Site 3 - Orlando

North Carolina

  • Takeda Site 8 - Denver
  • Takeda Site 6 - Huntersville

Other

  • Takeda Site 15 - Paris
  • Takeda Site 23 - Bologna

Colorado

  • Takeda Site 1 - Colorado Springs

Missouri

  • Takeda Site 4 - St Louis

Ohio

  • Takeda Site 5 - Cincinnati

South Carolina

  • Takeda Site 2 - Columbia

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2025-05-06
Est. Completion 2026-08-20
Phase Phase 2
Takeda

408 total trials

What NCT06952699 shows while recruiting

NCT06952699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 112-participant average among 4 other Narcolepsy Type 2 trials with a reported enrollment target (21% lower).

The record links to 1 condition, with Narcolepsy Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06952699 names 20 study sites across 16 states, led by California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06952699 about?

NCT06952699 is a clinical study titled "A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)". Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night...

What is the current status of trial NCT06952699?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2025-05-06. Estimated completion is 2026-08-20.

What conditions does trial NCT06952699 study?

This clinical trial studies the following conditions: Narcolepsy Type 2.

What interventions are being tested in trial NCT06952699?

The interventions under investigation include: Placebo (OTHER), TAK-360 (DRUG).

Who is sponsoring clinical trial NCT06952699?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06952699 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Narcolepsy Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06952699, the US trial registry maintained by the National Library of Medicine. NCT06952699 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.